Amgen Inc. (NASDAQ:AMGN) Shares Sold by Pictet Asset Management Ltd.
Pictet Asset Management Ltd. decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 10.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,346,444 shares of the medical research company’s stock after selling 155,887 shares during the period. Amgen comprises about 0.7% of Pictet Asset Management Ltd.’s portfolio, making the stock its 15th largest position. Pictet Asset Management Ltd. owned about 0.18% of Amgen worth $220,911,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of AMGN. Jackson Grant Investment Advisers Inc. increased its position in shares of Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares during the last quarter. First Command Financial Services Inc. increased its position in shares of Amgen by 1.1% in the first quarter. First Command Financial Services Inc. now owns 1,547 shares of the medical research company’s stock valued at $254,000 after buying an additional 17 shares during the last quarter. Cribstone Capital Management LLC increased its position in shares of Amgen by 2.3% in the first quarter. Cribstone Capital Management LLC now owns 1,113 shares of the medical research company’s stock valued at $182,000 after buying an additional 25 shares during the last quarter. Cable Hill Partners LLC increased its position in shares of Amgen by 2.7% in the first quarter. Cable Hill Partners LLC now owns 982 shares of the medical research company’s stock valued at $161,000 after buying an additional 26 shares during the last quarter. Finally, Howe & Rusling Inc. increased its position in shares of Amgen by 1.1% in the first quarter. Howe & Rusling Inc. now owns 2,956 shares of the medical research company’s stock valued at $485,000 after buying an additional 31 shares during the last quarter. 78.87% of the stock is owned by hedge funds and other institutional investors.
Amgen Inc. (NASDAQ AMGN) opened at 175.89 on Thursday. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $184.21. The firm’s 50 day moving average price is $171.84 and its 200-day moving average price is $166.15. The company has a market capitalization of $129.35 billion, a PE ratio of 16.71 and a beta of 1.36.
Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.37% and a net margin of 34.42%. The firm had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same period in the previous year, the firm earned $2.84 earnings per share. The business’s revenue was up 2.1% compared to the same quarter last year. On average, equities analysts anticipate that Amgen Inc. will post $12.48 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Amgen Inc. (NASDAQ:AMGN) Shares Sold by Pictet Asset Management Ltd.” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dailypolitical.com/2017/07/27/amgen-inc-nasdaqamgn-shares-sold-by-pictet-asset-management-ltd.html.
Several research analysts have commented on the company. Mizuho set a $195.00 target price on Amgen and gave the stock a “buy” rating in a research note on Saturday, May 6th. UBS AG reissued a “neutral” rating and set a $174.00 target price (down previously from $175.00) on shares of Amgen in a research note on Monday, May 22nd. BMO Capital Markets downgraded Amgen from an “outperform” rating to a “market perform” rating and set a $199.00 target price for the company. in a research note on Friday, July 21st. They noted that the move was a valuation call. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $203.00 price objective (up previously from $189.00) on shares of Amgen in a research note on Wednesday. Finally, Deutsche Bank AG reaffirmed a “hold” rating and issued a $174.00 price objective (up previously from $172.00) on shares of Amgen in a research note on Wednesday. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eleven have given a buy rating and three have issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $186.81.
In other news, SVP Cynthia M. Patton sold 2,922 shares of the business’s stock in a transaction that occurred on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total transaction of $451,156.80. Following the transaction, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.20% of the stock is currently owned by insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.